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    Kidney transplantation is the most common transplantation in the world. Annually, a large number of 
patients that have chronic renal failure are undergoing renal transplantation and the major subject about 
these patients is the rejection of graft that should be controlled by immunosuppressive agents.  The aim of 
this study is investigation of the effect of Cyclosporin against Tacrolimus in patients with kidney 
transplantation. This study was performing between 2010 and 2012 on all patients who had kidney 
transplantation and refer to Imam Reza hospital from Kermanshah University of Medical Sciences. 100 
patients, aged 18–60 years, with end-stage renal disease were administered either Tacrolimus (n=49) or 
Cyclosporine (n=51). In both groups, Cellept could be discontinued from day 92 onwards. Corticosteroid 
treatment comprised methylprednisolone boluses followed by a rapid prednisone taper from 20 mg (day 2) 
to 5 mg (day 43 and thereafter). Patients followed up 12 months.  
In the Tacrolimus treatment group, 7 grafts (14%) were lost and 8 (16%) grafts were lost in the Cyclosporine 
treatment group between months 0 and 12 and there is no significant different between these groups (P= 
0.845). No cases were diagnosed with biopsy-proven chronic rejection at months 0 and 12. Mean serum 
creatinine concentrations were 1.8 ± 1.5 mg/dl in the Tacrolimus group and 2.3 ±2.9 in the Cyclosporine 
group by month 12 (P= 0.348). these data are consistent with previously published observations and confirm 
that Tacrolim us is a highly efficacious baseline immunosuppressant for patients undergoing kidney 
transplantation. Tacrolimus-based immunosuppression may promote long-term benefits with regard to graft 
functio n and graft survival. 
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INTRODUCTION 
Renal transplantation is the treatment of 
choice for most patients with end stage renal 
disease and the number of new patients requiring 
renal transplantation for permanent kidney failure 
is increasing worldwide [1]. Calcineurin inhibitors 
are considered the mainstay of 
immunosuppression in renal transplantation [2]. 
Much of the success in organ transplantation has 
been credited to the use of Cyclosporine; after its 
introduction renal graft survival at 1 year 
increased from 64% to 78%. Despite the 
improvement in early graft function, long term 
kidney graft survival has not changed 
dramatically since the introduction of 
Cyclosporine [3]. The chronic loss of transplanted 
kidneys and the potential toxicity of Cyclosporine 
have prompted the development of other 
immunosuppressant drugs. Tacrolimus (FK506), a 
drug which has a similar mode of action to 
Cyclosporine, was first used in clinical 
transplantation in 1989 [4]. Benefits of treatment 
with Tacrolimus have included a reduction in 
steroid dose, a decreased need for 
 




antihypertensive drugs, and a lower serum 
cholesterol concentration [5, 6]. Pronounced 
global differences in use of Tacrolimus exist; 63% 
of new renal transplant recipients in the United 
States receive Tacrolimus for primary 
immunosuppression compared with only 22% in 
Australia [7, 8]. However, Cyclosporine and 
Tacrolimus are currently the most widely used 
baseline immunosuppressants for prevent ion of 
acute rejection following kidney transplantation. 
The aim of this study is compare the positive and 
negative effects of Tacrolimus and Cyclosporine 
as initial treatment for renal transplant recipients. 
 
MATERIAL AND METHODS 
This randomized, open study was conducted 
in Imam Reza hospital from Kermanshah 
University of Medical University, Iran between 
2010 and 2012. 100 patients, aged 18–60 years, 
with end-stage renal disease were administered 
either Tacrolimus (n=49) or Cyclosporine (n=51). 
The initial dose of Tacrolimus was 0.2 mg/kg/day 
to achieve target whole-blood trough levels of 10–
15 ng/ml in the first month post-transplant and 5–
10 ng/ml thereafter. Cyclosporine microemulsion 
was given at an initial dose of 8 mg/ kg/day with 
target levels of 150–250 ng/ml in the first month 
post-transplant and 100–150 ng/ml thereafter. In 
both groups, Cellept (1–2 mg/kg/day) could be 
discontinued from day 92 onwards. Corticosteroid 
treatment comprised methylprednisolone boluses 
(day 0: 500 mg; day 1: 125 mg) followed by a 
rapid prednisone taper from 20 mg (day 2) to 5 
mg (day 43 and thereafter). Adverse events, 
laboratory parameters and renal function (serum 
Creatinine) and GFR (glomerular filtration rate) 
were recorded throughout the study. All statistical 
analysis was performed by using SPSS software 
version 16.0. Frequency and percentage were 
computed for categorical variables and mean and 
standard deviation were estimated for quantitative 
variables.  
RESULTS 
Demographic and baseline characteristics 
were similar between the two treatment groups 
(Table 1). Of the original 100 patients randomized 
to treatment, 49 (49%) patients in the Tacrolimus 
treatment group and 51 (51%) patients in the 
Cyclosporine group were assessed at 1 year 
follow-up. In the Tacrolimus treatment group, 7 
grafts (14%) were lost and 8 (16%) grafts were 
lost in the Cyclosporine treatment group between 
months 0 and 12 and there is no significant 
different between these groups (P= 0.845) (Table 
2 and Figure 1). No cases were diagnosed with 
biopsy-proven chronic rejection at months 0 and 
12. Mean serum creatinine concentrations were 
1.7 ± 1.1 mg/dl in the Tacrolimus group and 1.7 
±1.3 mg/dl in the Cyclosporine group by month 6. 
Mean serum creatinine concentrations were 1.8 ± 
1.5 mg/dl in the Tacrolimus group and 2.3 ±2.9 in 
the Cyclosporine group by month 12 (P= 0.348) 
(Figure 2). Also, there is no significant different 
in GFR between these two groups by month 12 
(P= 0.572) (Table 3) 
 
 
Figure 1. Graft survival rate 
 
 




Tacrolimus (n=49) 34 (69.3%) 15 (30.6%) 40.4 ± 15.6 58.1 ± 5.6 
Cyclosporine (n=51) 35 (68.6%) 16 (31.3%) 37.1 ± 12.9  61.5 ± 5.8 


























Table 2. Incidence of acute rejection 
Acute Rejection Tacrolimus (n=49) Cyclosporine (n=51) P value 
0-1 month 4 (8%) 2 (4%) 0.432 
1-3 month 1 (2%) 2 (4%) 0.999 
3-6 month 1 (2%) 1 (2%) 0.999 
 6-9 month 1 (2%) 2 (4%) 0.999 
9-12 month 0 (0%) 1 (2%) 0.999 
Total 7 (14%) 8 (16%) 0.845 
 
 
Figure 2. Serum creatinine concentrations in patients 
 
Table 3. Renal function based on GFR measurement in 0-12 month 
GFR Tacrolimus (n=49) Cyclosporine (n=51) P value 
0-1 51.6±28.1 68.8±15.4 0.158 
1-3 47.8±25.2 59.3±18 0.304 
3-6 45.3±21.9 49.6±26.8 0.806 
6-9 44.7±25 46.2±32.3 0.915 
9-12 41±28.5 35.2±39.1 0.572 
 
DISCUSSION 
In renal transplantation, a reduced incidence 
of acute rejection and improved 1-year graft 
survival in recent years ha s necessitated 
investigation of additional clinically relevant 
parameters to differentiate between 
immunosuppressive strategies. Our data showed 
there is no significant different between these two 
treatments. However, according to lower mean of 
serum creatinine concentration and lower total 
acute rejection in Tacrolimus group it seems to be 
this agent is better than Cyclosporine treatment. In 
compare to our study, two large, randomized, 
multicentre studies conducted in Europe and the 
US demonstrated that the incidence of acute 
rejection was significantly less in 508 renal 
transplant recipients receiving Tacrolimus-based 
immunosuppression compared with 355 receiving 
Cyclosporine-based immunosuppression [9, 10]. 
Projected graft half-life was longer and chronic 
rejection less frequent with Tacrolimus-based 
immunosuppression at 5 year follow-up [9]. 
Furthermore, renal function better after 5 years in 
patients receiving Tacrolimus-based 
immunosuppression compared with Cyclosporine-
based immunosuppression [10]. In another long-
term data from the Tacrolimus vs Cyclosporine 
Kidney Transplant Study (randomization of 232 
patients to Tacrolimus or Cyclosporine 































demonstrated higher 6 year graft survival, longer 
estimated graft half-life and significantly better 
renal function (GFR) with Tacrolimus [11]. 
Gjertson et al reported a significant improvement 
in long term renal graft survival for recipients of 
Tacrolimus based immunosuppression. Patients 
who received Tacrolimus had a renal allograft 
half life of 13.8 years compared with 8.8 years for 
recipients of Cyclosporine based treatment [3]. 
Further, Kramer et al concluded Tacrolimus-
based immunosuppression may induce long-term 
benefits with regard to graft function and graft 
survival [12]. Webster et al in his meta-analysis 
concluded, in compared with cyclosporine, 
treating kidney transplant recipients with 
Tacrolimus resulted in a substantial improvement 
in graft survival —a 44% reduction in graft loss 
(censored for death) within the first six months, 
an effect revealed for the first time by his meta-
analysis and not evident when considering each 
trial in isolation. Treating with Tacrolimus led to 
31% fewer patients having acute rejection and 
51% fewer having severe rejection that needed 
treatment more intensive than steroids, within the 
first year [13]. In conclusion, these data are 
consistent with previously published observations 
and confirm that Tacrolim us is a highly 
efficacious baseline immunosuppressant for 
patients undergoing kidney transplantation. 
Tacrolimus-based immunosuppression may 
promote long-term benefits with regard to graft 
functio n and graft survival. 
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